{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T19:16:08Z","timestamp":1789240568850,"version":"build-2803163510"},"reference-count":22,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T00:00:00Z","timestamp":1729641600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"<jats:p>This case report presents a comprehensive evaluation of the complex balance of therapeutic benefits and potential risks associated with the cystic fibrosis transmembrane conductance regulator (CFTR) modulator elexacaftor\/tezacaftor\/ivacaftor (ETI) therapy in managing an eight-year-old male with cystic fibrosis (CF) and exocrine pancreatic insufficiency (EPI). While ETI therapy significantly enhanced exocrine pancreatic function, it led to hepatotoxicity, necessitating therapy discontinuation. Attempts to restart ETI at reduced doses were unsuccessful due to persistent hepatic dysfunction. Reduced ETI dosing frequency, implemented due to hepatic dysfunctions, did not result in substantial therapeutic benefits. Clinical markers showed a resurgence of severe EPI and sustained need for gastrostomy tube feeds, with only modest improvement in hepatic function compared to the period following ETI cessation or during prior use of CFTR modulator therapy with lumacaftor\/ivacaftor. This case underscores the importance of personalized therapeutic approaches, biomarker-guided monitoring, and multidisciplinary insights to optimize CF management while also highlighting the ongoing need for research to mitigate hepatotoxicity risks and ensure long-term therapeutic efficacy.<\/jats:p>","DOI":"10.3389\/fped.2024.1457517","type":"journal-article","created":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T05:00:27Z","timestamp":1729659627000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Case Report: A delicate equilibrium of exocrine pancreatic recovery and hepatotoxicity with elexacaftor\/tezacaftor\/ivacaftor therapy in a pediatric patient with cystic fibrosis"],"prefix":"10.3389","volume":"12","author":[{"given":"Michael P.","family":"Coughlin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Senthilkumar","family":"Sankararaman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica A.","family":"Roesch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily D.","family":"Certo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin L.","family":"Brej","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael W.","family":"Konstan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,10,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.jcf.2022.01.009","article-title":"Worldwide rates of diagnosis and effective treatment for cystic fibrosis","volume":"21","author":"Guo","year":"2022","journal-title":"J Cyst Fibros"},{"key":"B2","doi-asserted-by":"publisher","first-page":"2519","DOI":"10.1016\/S0140-6736(16)00576-6","article-title":"Cystic fibrosis","volume":"388","author":"Elborn","year":"2016","journal-title":"Lancet"},{"key":"B3","doi-asserted-by":"publisher","first-page":"S70","DOI":"10.1016\/j.jcf.2017.06.011","article-title":"Pancreatic insufficiency in cystic fibrosis","volume":"16","author":"Singh","year":"2017","journal-title":"J Cyst Fibros"},{"key":"B4","doi-asserted-by":"publisher","first-page":"914790","DOI":"10.3389\/fped.2022.914790","article-title":"The exocrine pancreas in cystic fibrosis in the era of CFTR modulation: a mini review","volume":"10","author":"McKay","year":"2022","journal-title":"Front Pediatr"},{"key":"B5","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.jcf.2006.01.005","article-title":"Fecal elastase-1: utility in pancreatic function in cystic fibrosis","volume":"5","author":"Daftary","year":"2006","journal-title":"J Cyst Fibros"},{"key":"B6","doi-asserted-by":"publisher","first-page":"101637","DOI":"10.1016\/j.cppeds.2024.101637","article-title":"Update on advances in cystic fibrosis towards a cure and implications for primary care clinicians","volume":"54","author":"Terlizzi","year":"2024","journal-title":"Curr Probl Pediatr Adolesc Health Care"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.3389\/fphar.2019.01662","article-title":"CFTR modulators: the changing face of cystic fibrosis in the era of precision medicine","volume":"10","author":"Lopes-Pacheco","year":"2020","journal-title":"Front Pharmacol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.3389\/fphys.2018.01585","article-title":"Cystic fibrosis of the pancreas: the role of CFTR channel in the regulation of intracellular Ca2+ signaling and mitochondrial function in the exocrine pancreas","volume":"9","author":"Mad\u00e1csy","year":"2018","journal-title":"Front Physiol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/S2213-2600(15)00545-7","article-title":"Safety, pharmacokinetics, and pharmacodynamics of ivacaftor in patients aged 2\u20135 years with cystic fibrosis and a CFTR gating mutation (KIWI): an open-label, single-arm study","volume":"4","author":"Davies","year":"2016","journal-title":"Lancet Respir Med"},{"key":"B10","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1016\/j.jcf.2019.03.009","article-title":"An open-label extension study of ivacaftor in children with CF and a CFTR gating mutation initiating treatment at age 2\u20135 years (KLIMB)","volume":"18","author":"Rosenfeld","year":"2019","journal-title":"J Cyst Fibros"},{"key":"B11","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1002\/ppul.26794","article-title":"Elexacaftor\/tezacaftor\/ivacaftor can rescue pancreatic function in F508del homozygous children","volume":"59","author":"Nathan","year":"2024","journal-title":"Pediatr Pulmonol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1016\/j.jcf.2023.09.005","article-title":"Changes in fecal elastase-1 following initiation of CFTR modulator therapy in pediatric patients with cystic fibrosis","volume":"22","author":"Stephenson","year":"2023","journal-title":"J Cyst Fibros"},{"key":"B13","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1164\/rccm.202102-0509OC","article-title":"A phase 3 open-label study of elexacaftor\/tezacaftor\/ivacaftor in children aged 6 through 11 years with cystic fibrosis and at least one F508del allele","volume":"203","author":"Zemanick","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"key":"B14","volume-title":"TRIKAFTA\u00ae (Elexacaftor, Tezacaftor, and Ivacaftor Tablets; Ivacaftor Tablets), co-Packaged for Oral use. Prescribing Information","year":"2023"},{"key":"B15","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.jcf.2022.10.003","article-title":"Elexacaftor\/tezacaftor\/ivacaftor and gastrointestinal outcomes in cystic fibrosis: report of PROMISE-GI","volume":"22","author":"Schwarzenberg","year":"2023","journal-title":"J Cyst Fibros"},{"key":"B16","article-title":"Cystic fibrosis agents","volume-title":"LiverTox: Clinical and Research Information on Drug-Induced Liver Injury","year":"2012"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1007\/s40265-023-01969-3","article-title":"Aetiology of significant liver test abnormalities in a single-centre cohort of people with cystic fibrosis exposed to elexacaftor\/tezacaftor\/ivacaftor, utilizing the updated RUCAM","volume":"83","author":"Tewkesbury","year":"2023","journal-title":"Drugs"},{"key":"B18","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1016\/j.jcf.2024.01.001","article-title":"Drug-induced liver injury associated with elexacaftor\/tezacaftor\/ivacaftor: a pharmacovigilance analysis of the FDA adverse event reporting system (FAERS)","volume":"23","author":"Shi","year":"2024","journal-title":"J Cyst Fibros"},{"key":"B19","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1016\/j.jcf.2021.05.017","article-title":"A case of self-limited drug induced liver injury under treatment with elexacaftor\/tezacaftor\/ivacaftor: when it is worth taking the risk","volume":"20","author":"Stylemans","year":"2021","journal-title":"J Cyst Fibros"},{"key":"B20","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1016\/j.jcf.2024.04.006","article-title":"Safety and efficacy of elexacaftor\/tezacaftor\/ivacaftor in people with cystic fibrosis following liver transplantation: a systematic review","volume":"23","author":"Testa","year":"2024","journal-title":"J Cyst Fibros"},{"key":"B21","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1016\/j.jcf.2024.02.001","article-title":"Heterogeneity of CFTR modulator-induced sweat chloride concentrations in people with cystic fibrosis","volume":"23","author":"Zemanick","year":"2024","journal-title":"J Cyst Fibros"},{"key":"B22","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1016\/S2213-2600(22)00504-5","article-title":"Safety and efficacy of vanzacaftor-tezacaftor-deutivacaftor in adults with cystic fibrosis: randomised, double-blind, controlled, phase 2 trials","volume":"11","author":"Uluer","year":"2023","journal-title":"Lancet Respir Med"}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2024.1457517\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T05:00:29Z","timestamp":1729659629000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2024.1457517\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,23]]},"references-count":22,"alternative-id":["10.3389\/fped.2024.1457517"],"URL":"https:\/\/doi.org\/10.3389\/fped.2024.1457517","relation":{},"ISSN":["2296-2360"],"issn-type":[{"value":"2296-2360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,23]]},"article-number":"1457517"}}